CYB5D2 Requires Heme-Binding to Regulate HeLa Cell Growth and Confer Survival from Chemotherapeutic Agents

The cytochrome b5 domain containing 2 (CYB5D2; Neuferricin) protein has been reported to bind heme, however, the critical residues responsible for heme-binding are undefined. Furthermore, the relationship between heme-binding and CYB5D2-mediated intracellular functions remains unknown. Previous studies examining heme-binding in two cytochrome b5 heme-binding domain-containing proteins, damage-associated protein 1 (Dap1; Saccharomyces cerevisiae) and human progesterone receptor membrane component 1 (PGRMC1), have revealed that conserved tyrosine (Y) 73, Y79, aspartic acid (D) 86, and Y127 residues present in human CYB5D2 may be involved in heme-binding. CYB5D2 binds to type b heme, however, only the substitution of glycine (G) at D86 (D86G) within its cytochrome b5 heme-binding (cyt-b5) domain abolished its heme-binding ability. Both CYB5D2 and CYB5D2(D86G) localize to the endoplasmic reticulum. Ectopic CYB5D2 expression inhibited cell proliferation and anchorage-independent colony growth of HeLa cells. Conversely, CYB5D2 knockdown and ectopic CYB5D2(D86G) expression increased cell proliferation and colony growth. As PGRMC1 has been reported to regulate the expression and activities of cytochrome P450 proteins (CYPs), we examined the role of CYB5D2 in regulating the activities of CYPs involved in sterol synthesis (CYP51A1) and drug metabolism (CYP3A4). CYB5D2 co-localizes with cytochrome P450 reductase (CYPOR), while CYB5D2 knockdown reduced lanosterol demethylase (CYP51A1) levels and rendered HeLa cells sensitive to mevalonate. Additionally, knockdown of CYB5D2 reduced CYP3A4 activity. Lastly, CYB5D2 expression conferred HeLa cell survival from chemotherapeutic agents (paclitaxel, cisplatin and doxorubicin), with its ability to promote survival being dependent on its heme-binding ability. Taken together, this study provides evidence that heme-binding is critical for CYB5D2 in regulating HeLa cell growth and survival, with endogenous CYB5D2 being required to modulate CYP activities.

[1]  T. Olczak,et al.  Binding Specificity of the Porphyromonas gingivalis Heme and Hemoglobin Receptor HmuR, Gingipain K, and Gingipain R1 for Heme, Porphyrins, and Metalloporphyrins , 2001, Journal of bacteriology.

[2]  E. Szczesna-Skorupa,et al.  Progesterone Receptor Membrane Component 1 Inhibits the Activity of Drug-Metabolizing Cytochromes P450 and Binds to Cytochrome P450 Reductase , 2011, Molecular Pharmacology.

[3]  R. A. Goldbeck,et al.  Spectroscopic and biochemical characterization of heme binding to yeast Dap1p and mouse PGRMC1p. , 2005, Biochemistry.

[4]  M Eileen Dolan,et al.  Clinically relevant genetic variations in drug metabolizing enzymes. , 2011, Current drug metabolism.

[5]  L. Tao,et al.  CYB5D2 enhances HeLa cells survival of etoposide-induced cytotoxicity. , 2011, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[6]  M. Bard,et al.  Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes. , 2007, Cell metabolism.

[7]  J. Peluso,et al.  Progesterone receptor membrane component 1—Many tasks for a versatile protein , 2008, Steroids.

[8]  F. Guengerich,et al.  Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. , 1994, Cancer research.

[9]  V. Freedman,et al.  Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[10]  G. Tsujimoto,et al.  Neuferricin, a novel extracellular heme‐binding protein, promotes neurogenesis , 2010, Journal of neurochemistry.

[11]  Mingjie Zhang,et al.  Cyclin-dependent Kinase 5 (Cdk5) Activation Domain of Neuronal Cdk5 Activator , 1997, The Journal of Biological Chemistry.

[12]  G. Vinson,et al.  Molecular identification of adrenal inner zone antigen as a heme‐binding protein , 2005, The FEBS journal.

[13]  D. Trono,et al.  A Third-Generation Lentivirus Vector with a Conditional Packaging System , 1998, Journal of Virology.

[14]  M. Bard,et al.  Biochemistry, cell biology and molecular biology of lipids of Saccharomyces cerevisiae , 1998, Yeast.

[15]  M. Cahill.  Progesterone receptor membrane component 1: An integrative review , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[16]  D. Russell,et al.  Clinical importance of the cytochromes P450 , 2002, The Lancet.

[17]  C. Flück,et al.  NADPH P450 oxidoreductase: structure, function, and pathology of diseases. , 2013, Pharmacology & therapeutics.

[18]  Stephen L. Abrams,et al.  Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. , 2007, Biochimica et biophysica acta.

[19]  M. Konishi,et al.  Functions of MAPR (membrane-associated progesterone receptor) family members as heme/steroid-binding proteins. , 2012, Current protein & peptide science.

[20]  Amy S. Lee,et al.  Regulation of the glucose‐regulated protein genes by β‐mercaptoethanol requires de novo protein synthesis and correlates with inhibition of protein glycosylation , 1987, Journal of cellular physiology.

[21]  R. Craven,et al.  Regulation of Iron Homeostasis Mediated by the Heme-binding Protein Dap1 (Damage Resistance Protein 1) via the P450 Protein Erg11/Cyp51* , 2007, Journal of Biological Chemistry.

[22]  U. Zanger,et al.  Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the “Missing Heritability” Problem , 2013, Front. Genet..

[23]  S. Merchant,et al.  Assembly of chloroplast cytochromes b and c. , 2000, Biochimie.

[24]  M. Schwab,et al.  Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation , 2008, Analytical and bioanalytical chemistry.

[25]  B. Trumpower,et al.  Simultaneous determination of hemes a, b, and c from pyridine hemochrome spectra. , 1987, Analytical biochemistry.

[26]  M. Bard,et al.  Saccharomyces cerevisiae Dap1p, a Novel DNA Damage Response Protein Related to the Mammalian Membrane-Associated Progesterone Receptor , 2003, Eukaryotic Cell.

[27]  R. H. Gray,et al.  Correlation of anchorage-independent growth with tumorigenicity of chemically transformed mouse epidermal cells. , 1978, Cancer research.

[28]  J. Markley,et al.  Letter to the Editor: Hypothetical protein At2g24940.1 from Arabidopsis thaliana has a cytochrome b5 like fold* , 2004, Journal of biomolecular NMR.

[29]  J. Sambrook,et al.  S. cerevisiae encodes an essential protein homologous in sequence and function to mammalian BiP , 1989, Cell.

[30]  M. Waterman,et al.  Sterol 14alpha-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms. , 2007, Biochimica et biophysica acta.

[31]  M. Osmak,et al.  The characterization of two human cervical carcinoma HeLa sublines resistant to cisplatin , 1993, Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie.

[32]  R. Craven,et al.  Hpr6 (Heme-1 Domain Protein) Regulates the Susceptibility of Cancer Cells to Chemotherapeutic Drugs , 2006, Journal of Pharmacology and Experimental Therapeutics.

[33]  M. Waterman,et al.  Sterol 14α-Demethylase Cytochrome P450 (CYP51), a P450 in all Biological Kingdoms , 2007 .

[34]  M. Bard,et al.  Dap1p, a Heme-Binding Protein That Regulates the Cytochrome P450 Protein Erg11p/Cyp51p in Saccharomyces cerevisiae , 2005, Molecular and Cellular Biology.

[35]  Kazuo Shinozaki,et al.  A structure‐based strategy for discovery of small ligands binding to functionally unknown proteins: Combination of in silico screening and surface plasmon resonance measurements , 2005, Proteomics.

[36]  V. Freedman,et al.  Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. , 1974, Cell.

[37]  T. Olczak,et al.  Heme environment in HmuY, the heme-binding protein of Porphyromonas gingivalis. , 2009, Biochemical and biophysical research communications.

[38]  Fanbo Zeng,et al.  Increase of doxorubicin sensitivity for folate receptor positive cells when given as the prodrug N-(phenylacetyl) doxorubicin in combination with folate-conjugated PGA. , 2006, Journal of pharmaceutical sciences.

[39]  R. Craven,et al.  PGRMC1 (progesterone receptor membrane component 1): a targetable protein with multiple functions in steroid signaling, P450 activation and drug binding. , 2009, Pharmacology & therapeutics.

[40]  R. Craven,et al.  Progesterone Receptor Membrane Component 1 (Pgrmc1): A Heme-1 Domain Protein That Promotes Tumorigenesis and Is Inhibited by a Small Molecule , 2010, Journal of Pharmacology and Experimental Therapeutics.

[41]  J. Cigudosa,et al.  Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas. , 2007, Blood.

[42]  Hajime Yamauchi,et al.  Neurotrophic Activity of Neudesin, a Novel Extracellular Heme-binding Protein, Is Dependent on the Binding of Heme to Its Cytochrome b5-like Heme/Steroid-binding Domain* , 2008, Journal of Biological Chemistry.

[43]  J. Sambrook,et al.  Protein folding in the cell , 1992, Nature.

[44]  Peter J Espenshade,et al.  Regulation of sterol synthesis in eukaryotes. , 2007, Annual review of genetics.

[45]  P. Thomas,et al.  An improved staining procedure for the detection of the peroxidase activity of cytochrome P-450 on sodium dodecyl sulfate polyacrylamide gels. , 1976, Analytical biochemistry.

[46]  J. Schellens,et al.  The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. , 2007, Cancer treatment reviews.

[47]  E. Yim,et al.  Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. , 2005, Gynecologic oncology.

[48]  D. Tang,et al.  Characterization of sphere-propagating cells with stem-like properties from DU145 prostate cancer cells. , 2011, Biochimica et biophysica acta.